{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T12:05:51Z","timestamp":1792325151439,"version":"4.4.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40291-026-00859-0","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T08:21:22Z","timestamp":1781770882000},"page":"839-844","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tividenofusp Alfa: First Approval"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7191-7391","authenticated-orcid":false,"given":"Matt","family":"Shirley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"issue":"3","key":"859_CR1","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00431-007-0635-4","volume":"167","author":"JE Wraith","year":"2008","unstructured":"Wraith JE, Scarpa M, Beck M, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2008;167(3):267\u201377.","journal-title":"Eur J Pediatr"},{"key":"859_CR2","unstructured":"Scarpa M, Lampe C. Mucopolysaccharidosis type II. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews\u00ae. Seattle (WA): University of Washington, Seattle; 2007 [updated 28 Apr 2026]."},{"issue":"1","key":"859_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s13052-024-01769-9","volume":"50","author":"SJ Mao","year":"2024","unstructured":"Mao SJ, Chen QQ, Dai YL, et al. The diagnosis and management of mucopolysaccharidosis type II. Ital J Pediatr. 2024;50(1):207.","journal-title":"Ital J Pediatr"},{"key":"859_CR4","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.2147\/DDDT.S139601","volume":"11","author":"DA Whiteman","year":"2017","unstructured":"Whiteman DA, Kimura A. Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future. Drug Des Devel Ther. 2017;11:2467\u201380.","journal-title":"Drug Des Devel Ther"},{"key":"859_CR5","unstructured":"US FDA. AVLAYAH (tividenofusp alfa-eknm) for injection, for intravenous use: US prescribing information. 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/761485s000lbl.pdf. Accessed 8 May 2026."},{"issue":"19","key":"859_CR6","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.145445","volume":"6","author":"A Arguello","year":"2021","unstructured":"Arguello A, Meisner R, Thomsen ER, et al. Iduronate-2-sulfatase transport vehicle rescues behavioral and skeletal phenotypes in a mouse model of Hunter syndrome. JCI Insight. 2021;6(19):e145445.","journal-title":"JCI Insight"},{"issue":"545","key":"859_CR7","doi-asserted-by":"publisher","first-page":"eaay1163","DOI":"10.1126\/scitranslmed.aay1163","volume":"12","author":"JC Ullman","year":"2020","unstructured":"Ullman JC, Arguello A, Getz JA, et al. Brain delivery and activity of a lysosomal enzyme using a blood-brain barrier transport vehicle in mice. Sci Transl Med. 2020;12(545):eaay1163.","journal-title":"Sci Transl Med."},{"issue":"1","key":"859_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMoa2508681","volume":"394","author":"J Muenzer","year":"2026","unstructured":"Muenzer J, Burton BK, Harmatz P, et al. An intravenous brain-penetrant enzyme therapy for mucopolysaccharidosis II. N Engl J Med. 2026;394(1):39\u201350.","journal-title":"N Engl J Med"},{"key":"859_CR9","unstructured":"US FDA. FDA approves drug to treat neurologic manifestations of Hunter syndrome [media release]. 25 Mar 2026. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-drug-treat-neurologic-manifestations-hunter-syndrome."},{"key":"859_CR10","unstructured":"Denali Therapeutics. Denali Therapeutics receives Orphan Drug and Rare Pediatric Disease designation for DNL310, and expands its portfolio of brain penetrant enzyme replacement programs [media release]. 11 Jun 2019. https:\/\/investors.denalitherapeutics.com\/news-releases\/news-release-details\/denali-therapeutics-receives-orphan-drug-and-rare-pediatric."},{"key":"859_CR11","unstructured":"Denali Therapeutics. Denali Therapeutics announces Fast Track designation granted by the U.S. FDA to ETV:IDS (DNL310) for the treatment of patients with Hunter syndrome (MPS II) [media release]. 11 Mar 2021. https:\/\/investors.denalitherapeutics.com\/news-releases\/news-release-details\/denali-therapeutics-announces-fast-track-designation-granted-us."},{"key":"859_CR12","unstructured":"Denali Therapeutics. Denali Therapeutics announces U.S. FDA Breakthrough Therapy designation granted to tividenofusp alfa for the treatment of Hunter syndrome (MPS II) [media release]. 08 Jan 2025. https:\/\/investors.denalitherapeutics.com\/news-releases\/news-release-details\/denali-therapeutics-announces-us-fda-breakthrough-therapy."},{"key":"859_CR13","unstructured":"Denali Therapeutics. SEC filing 10K. 2023. https:\/\/www.sec.gov\/ix?doc=\/Archives\/edgar\/data\/1714899\/000171489923000049\/dnli-20221231.htm. Accessed 8 May 2026."},{"key":"859_CR14","unstructured":"F-star. F-star announces collaborative agreement with Denali Therapeutics for the development of a multispecific antibody platform to deliver therapeutics across the blood-brain barrier [media release]. 25 Aug 2016. https:\/\/www.nature.com\/articles\/d43747-020-00163-8."},{"key":"859_CR15","unstructured":"Denali Therapeutics. Denali Therapeutics announces early exercise of its option to acquire F-star Gamma [media release]. 30 May 2018. https:\/\/investors.denalitherapeutics.com\/news-releases\/news-release-details\/denali-therapeutics-announces-early-exercise-its-option-acquire."},{"key":"859_CR16","unstructured":"Denali Therapeutics Inc. SEC filing 10K. 2022. https:\/\/www.sec.gov\/ix?doc=\/Archives\/edgar\/data\/1714899\/000171489922000058\/dnli-20211231.htm. Accessed 8 May 2026."},{"issue":"2","key":"859_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2022.106996","volume":"138","author":"JA Rodriguez","year":"2023","unstructured":"Rodriguez JA, Harris J, Cygon P, et al. COMPASS, a double-blinded randomized phase 2\/3 study of the efficacy and safety of intravenous DNL310 (brain-penetrant enzyme replacement therapy) in MPS II. Mol Genet Metab. 2023;138(2):106996.","journal-title":"Mol Genet Metab"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-026-00859-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-026-00859-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-026-00859-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T19:02:48Z","timestamp":1787425368000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-026-00859-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["859"],"URL":"https:\/\/doi.org\/10.1007\/s40291-026-00859-0","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"7 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Matt Shirley is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":1,"name":"Ethics","label":"Authorship and Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}